Synapse - William Johnson

Results (45)

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation

Meeting Abstract

Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
Blood (2022)

Fulltext@MSK | Save

Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing

Meeting Abstract

Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2022)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling

Meeting Abstract

Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant

Meeting Abstract

Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

Current treatment of peripheral T-cell lymphoma

Review

Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Lewis, N.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.
Oncology (Norwalk) (2022)

Fulltext@MSK | Save

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)